IPCA Labs Q1 FY27: Standalone Net Profit Up 42% to ₹373 Cr, Consolidated Up 80% to ₹423 Cr
IPCA Laboratories reported strong Q1 FY27 results. Standalone net profit increased 42% to ₹373.29 crore, and consolidated net profit rose 80% to ₹422.81 crore. Total income grew 20-21% year-on-year. Indian formulations income was up 13%, and exports increased 34%.
The substantial increase in net profit and revenue for both standalone and consolidated results, coupled with improved margins, is a material development for the company's financial health and investor outlook.
The company reported significant year-on-year growth in both standalone and consolidated net profit, along with revenue and EBITDA margin improvements, indicating positive financial performance.
IPCA Laboratories Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a standalone net total income of ₹2,136.66 crore, an increase of 21% from the previous year. Consolidated net total income grew by 20% to ₹2,813.36 crore.
On the profit front, standalone net profit surged by 42% to ₹373.29 crore, while consolidated net profit saw a significant jump of 80% to ₹422.81 crore. The company's EBITDA margins also improved, with standalone EBITDA margin at 26.27% and consolidated EBITDA margin at 22.88% for Q1 FY27.
Revenue from Indian formulations increased by 13% to ₹1,082.12 crore, and exports income rose by 34% to ₹935.39 crore. The Board of Directors met on August 13, 2026, to approve these results. The meeting commenced at 12:00 noon and concluded at 1:30 p.m.
What to do with a filing like this
IPCA Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IPCA Laboratories Limited. Read the original for the full detail.